Intervention Review

You have free access to this content

Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack

  1. Jia Liu*,
  2. Lu-Ning Wang

Editorial Group: Cochrane Stroke Group

Published Online: 8 JAN 2014

Assessed as up-to-date: 14 OCT 2013

DOI: 10.1002/14651858.CD010693.pub2


How to Cite

Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD010693. DOI: 10.1002/14651858.CD010693.pub2.

Author Information

  1. Chinese PLA General Hospital, Department of Geriatric Neurology, Beijing, China

*Jia Liu, Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, 100853, China. Jason_liu1984@163.com.

Publication History

  1. Publication Status: New
  2. Published Online: 8 JAN 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
J-SPIRIT {published data only}
  • Tanaka R, Okuma Y, Miyamoto N, Tanaka Y, Yamashiro K, Watada H, et al. Effects of pioglitazone in patients with impaired glucose tolerance after stroke; progress report from J-SPIRIT study. International Journal of Stroke 2010;5:195 (Abst.PO10427).
  • Tanaka R, Yamashiro K, Tanaka Y, Miyamoto N, Ueno Y, Watanabe M, et al. Effects of pioglitazone in patients with abnormal glucose metabolism after stroke. The J-SPIRIT study. Stroke 2013;44:Abst.ATP416.
Kernan 2003 {published data only}
  • Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003;34:1431-6.
Marfella 2006 {published data only}
  • Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. Journal of the American College of Cardiology 2006;47:2444-55.
PROactive {published data only}
  • Anonymous. PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCI (Actos) therapy. Cardiovascular Journal of South Africa 2005;16:286-7.
  • Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, on behalf of the PROactive Study Group. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). Diabetes Care 2004;27:1647-53.
  • Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L, on behalf of the PROactive investigators. Impact of peripheral arterial disease in patients with diabetes - results from PROactive (PROactive 11). Atherosclerosis 2009;202:272-81.
  • Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
  • Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: Pioglitazone in the treatment of type 2 diabetes: Results of the PROactive study. Vascular Health and Risk Management 2007;3:355-70.
  • Erdmann E, Spanheimer R, Charbonnel B. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Journal of Diabetes 2010;2:212-20.
  • Wilcox R, Bousser MG, Betteridge J, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73.
  • Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). American Heart Journal 2008;155:712-7.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
CIMT Trial {published data only}
Dehnavi 2005 {published data only}
  • Dehnavi RA. A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes. Nederlands Trial Register (http://www.trialregister.nl) 2005.
Forst 2008 {published data only}
  • Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diabetes and Vascular Disease Research 2008;5:298-303.
Hedblad 2007 {published data only}
Koshiyama 2001 {published data only}
  • Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001;86:3452-6.
Meisner 2006 {published data only}
  • Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arteriosclerosis Thrombosis and Vascular Biology 2006;26:845-50.
Sidhu 2004 {published data only}
  • Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients with diabetes mellitus. Arteriosclerosis Thrombosis and Vascular Biology 2004;24:930-4.
TART {published data only}
TIDE {published data only}
  • GlaxoSmithKline. Thiazolidinedione Intervention With Vitamin D Evaluation (TIDE). ClinicalTrials.gov 2009.
TRIPOD {published data only}
  • Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Controlled Clinical Trials 1998;19:217-31.
  • Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008;199:207-14.
  • Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005;90:1986-91.
Varghese 2009 {published data only}
  • Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, et al. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance 2009;11:24.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
IRIS {published data only}
  • Insulin Resistance Intervention After Stroke Trial (IRIS). http://clinicaltrials.gov/ct2/show/NCT00091949.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Collino 2010
Costa 2005
  • Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004296.pub2]
Dasu 2009
De Schryver 2007
De Schryver 2012
Egger 1997
  • Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
Els 2002
  • Els T, Klisch J, Orszagh M, Hetzel A, Schulte-Mönting J, Schumacher M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovascular Diseases 2002;13:89-94.
Emerging Risk Factors Collaboration 2010
  • Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
Fogg 2009
  • Fogg C, Kasliwal R, Shakir SA. Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. Drug Safety 2009;32:229-37.
Goldstein 2006
  • Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-633.
Graham 2010
  • Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-8.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Jørgensen 1997
  • Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997;48:891-5.
Melikian 2009
  • Melikian N, Seddon MD, Casadei B, Chowienczyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. Trends in Cardiovascular Medicine 2009;19:256-62.
Mooradian 2002
  • Mooradian AD, Chehade J, Thurman JE. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treatments in Endocrinology 2002;1:13-20.
Nakamura 2007
  • Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007;38:3016-22.
RevMan 2012
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
Sandercock 2009
Simon 2009
  • Simon RP, Greenberg DA, Aminoff MJ. Stroke. Clinical Neurology. 7th Edition. New York: McGraw-Hill, 2009:292-327.
Sudlow 2009
WHO 2010
  • World Health Organization. The atlas of heart disease and stroke. http://www.who.int/cardiovascular_diseases/resources/atlas/en (accessed 12 May 2013).